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Brown et al. begin by highlighting an article reviewing cross protection in different vaccine trials by Malag on et al., 1 which suggests that AS04-adjuvanted HPV16/18 (bHPV, Cervarix TM ) vaccine-mediated protection against non-vaccine HPV types 31, 33, and 45 is higher than that of the quadrivalent vaccine (Gardasil TM ), but that this protection may wane after 4 y, based on 6-month persistent infection data from the Phase III study PATRICIA (NCT00122681) (total vaccinated HPV-na€ ıve cohort (TVC-na€ ıve) n D 11,644) and the Phase II studies GSK HPV-001/007 (NCT00689741 and NCT00120848) (accordingto-protocol efficacy (ATP-E) cohort n D 919) and GSK HPV-001/007/023 (NCT00518336) (ATP-E cohort n D 395) with up to 4, 6.4 and 9.4 y follow-up, respectively.
2,3 They mention as additional evidence the analyses by Naud et al. and Saah et al. which, we would like to clarify, are in fact analyses of the same Phase II data (studies HPV 001/007/023) analyzed by Malag on et al. In reviewing these data, it appears to us that several key aspects, as explained in detail in a recently accepted review of the bHPV vaccine 4 should be considered as follows: First, in the Phase II studies, the number of persistent infections was very small (<10 subjects in the vaccine and control arms), resulting in very large confidence intervals that have lower limits reaching substantially below ¡100% for nearly all the estimates (Fig. 1) . Second, Malag on et al. base their conclusion of waning cross protection on the heterogeneity in vaccine efficacy between the 3 studies that seemed to decrease with increased follow-up, but it is unclear whether their heterogeneity analysis considered that HPV-001/007/023 was a follow-up of a sub-cohort of HPV-001/007 and not independent data. Third, the analyses do not consider the trials' incident infection data that are also publicly available in the clinical trial reports and show consistent efficacy at 6.4 and 9.4 y (Fig. 1) . 2, 3 These data are important to consider in addition to persistent infection data as: 1) incident infections occurred more frequently in the trials resulting in more robust efficacy estimates; and 2) efficacies against incident and persistent infections are expected to provide similar estimates if large enough populations are analyzed. 5 Finally, sustained efficacy against incident infections is supported by long-term immunogenicity data from HPV-001/ 007/023 showing sustained antibody titers against HPV31 and 45 up to 9.4 y after vaccination, 6 the longest follow-up of any HPV vaccine study to date. This raises the question as to what biologically plausible mechanism could explain such differences in the efficacies against incident and persistent infections while maintaining stable underlying antibody titres throughout the 9.4 y.
Furthermore, data from the 7 y follow-up of 5752 women aged > 25 y enrolled in the Phase III bHPV vaccine efficacy study VIVIANE (HPV-015, NCT00294047) were recently presented. 7 Despite being an older age group with consequently less vigorous immune responses, efficacy in the ATP-E cohort against persistent HPV31 and 45 infections after 7 y was significant and consistent with the 4 y follow-up: 65.8% (96.2% CI 24.9-85.8) and 79.1% (97.7% CI 27.6-95.9), respectively, for 31; 70.7% (96.2% CI 34.2-88.4) and 76.9% (97.7% CI 18.5-95.6), respectively, for 45. 8 No effect was demonstrated for persistent HPV33 infections at 7 and 4 y (¡32.0, 96.2% CI ¡275.2-51.5, and ¡31.9%, 97.7% CI ¡460.8-66.3, respectively). Cross-protection has also been borne out in the realworld following introduction of universal mass vaccination with the bHPV vaccine in the United Kingdom from September 2008 until September 2012, with at least 2 doses of the bHPV vaccine being associated with > 50% reductions in the prevalence of HPV 31/33/45 among 20 to 21-year olds attending cervical cancer screening in Scotland (adjusted Odds Ratios: 0.46, 95% CI 0.21-0.94, for 2 doses; 0.45, 95% CI 0.29-0.68, for 3 doses). 9 Approximately 45% of the vaccinated girls were vaccinated at least 4 y earlier at age 15 to 16 y.
Brown et al. also mention reduced efficacy against persistent HPV31, 33 and 45 infections in women who received 2 vs. 3 doses in a combined analysis of PATRICIA and the Costa Rica Vaccine Trial. 5 However, this was a secondary analysis of a subset of women who had accidentally missed 1 or 2 doses and therefore probably unrepresentative of the total study sample. Interestingly this study observed a 1-dose vaccine efficacy against persistent HPV31, 33, and 45 infections that was higher than the 2-dose efficacy and similar in range to the 3-dose efficacy for these types. Furthermore, unlike vaccine-type efficacy, efficacy against HPV31, 33 and 45 was assessed only in the total vaccinated cohort, which included baseline positive women. It is well documented in various HPV vaccine efficacy trials that the inclusion of baseline HPV positive subjects results in lower efficacy estimates as the available prophylactic HPV vaccines have no therapeutic effect. In a corresponding Phase IIb/III study population including all women who received at least 1 dose of the 9-valent HPV (9vHPV) vaccine, the 9vHPV vaccine failed to show any efficacy against high grade lesions compared to the quadrivalent vaccine (Gardasil TM ), highlighting the complexity of efficacy analyses in cohorts that include HPV exposed individuals. 10 Brown et al. further present data from their own model, where the 9vHPV vaccine manages to achieve 100% elimination of CIN1, CIN2/3, and cancer at post-vaccination steady state even though it does not contain VLPs for at least 6 other oncogenic HPV types and data has shown that the 9vHPV vaccine does not prevent infection and disease related to HPV types beyond the 9 types covered by the vaccine. 10 As presented in a recent systematic review of the efficacy of HPV vaccines against cervical lesions, efficacy irrespective of HPV type is one of the most important parameters from a public health perspective. 11 Efficacy irrespective of type captures all vaccine effects against vaccine and non-vaccine HPV types and is not confounded by co-infections or general limitations of HPV testing. 12 The bHPV vaccine's efficacy irrespective of type against CIN2C is reported between 65% and 80% in HPV-na€ ıve women in 4 different trials with up to 6.4 y of follow up. [13] [14] [15] [16] Efficacy against CIN3C demonstrated in the Phase III study PATRICIA was 93.2% (CI 95% 78.9-98.7). In all trials, data has shown that the bHPV vaccine efficacy irrespective of type was higher than the contribution of HPV16/18 to lesions in the respective control groups, demonstrating consistent cross protection beyond the vaccine types. Reported efficacy estimates against CIN2C irrespective of type for the quadrivalent HPV vaccine in HPV na€ ıve women were 42.7%, 17 and 62.8% for the 9vHPV vaccine (against historical placebo group), 18 which is lower than in effectiveness projections based on epidemiological type distribution. 19 The projected elimination of CIN1, CIN2/3 and cancer in the long-term for the 9vHPV vaccine is therefore unexpected, however the methodological details, in particular the assumptions about efficacies and vaccination coverage, have not been presented in the Brown et al. letter.
Finally Brown et al. question the potentially lower quality of cross reactive antibodies vs. antibodies specific to vaccine HPV VLPs. Existing clinical data has shown that the crossprotective effects of the bHPV vaccine are in fact induced by the vaccine HPV VLPs (i.e., HPV16/18 VLPs), with the broader immune response, including a broad T-cell response, being likely attributable to the AS04 adjuvant contained in the bHPV vaccine. 20 Nonetheless, from a clinical point of view, what is most important is not the antigens themselves but the immune-response the vaccines induce and the effect they produce in terms of disease prevention. Regarding the cross-reactive antibody response, indeed the persistence of the cross-reactive antibody titers against HPV31 and 45 after bHPV vaccination has been evidenced up to 9.4 y 6 and the avidity of these cross-reactive antibodies has been tested for up to 4 y. 21 Until the duration and the quality of the immune-response induced by the 9vHPV vaccine is clinically evidenced for equivalent or longer follow-up periods, any projection on these aspects based on experience with other vaccines and on the manufacturing processes of the antigens seems speculative.
Taken together these data suggest that the demonstrated cross-protective efficacy of the bHPV vaccine is sustained in the long-term and should not be discarded as a "short-lived epiphenomenon." Abbreviations 9vHPV 9-valent HPV vaccine ATP-E According-to-protocol efficacy 
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